Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Feb 7, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a treatment called Mitomycin C is in preventing cancer from coming back in the bladder after a procedure called ureteroscopy, which is used to diagnose or treat upper urinary tract cancer. The study will follow patients for two years to see how many experience a recurrence of cancer in the bladder and how quickly that happens. Additionally, it will compare the results of patients who receive this treatment with those who did not in the past, and will also evaluate the outcomes of those who have further treatment, either through endoscopy or surgery to remove the kidney and ureter.

To be eligible for this trial, participants must be at least 18 years old and suspected of having non-metastatic upper urinary tract cancer, meaning the cancer has not spread beyond its original site. They need to be scheduled for a ureteroscopy and agree to receive Mitomycin C afterward. However, individuals with a history of bladder cancer or certain other medical conditions will not be included. If you join this study, you can expect to have your health monitored closely over the next two years to see how well the treatment works for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients suspect for having non-metastatic disease and planned for ureteroscopy (diagnostic or treatment) and adjuvant single instillation of Mitomycin C
• • Age ≥18 years
• • Written informed consent
• Exclusion Criteria:
• • History of histological proven urothelial carcinoma of the bladder, including carcinoma in situ
• • History of histological proven UTUC in the contralateral kidney
• • Concurrent bladder tumour found pre-operatively or per-operatively
• • Patients where it is not feasible to obtain histology by biopsies intra-operatively
• • Known Mitomycin C
• • Renal transplantation